Business Context and Reporting Period
This Form 8-K Current Report was filed by Cytosorbents Corp on June 15, 2011. The filing discloses the execution of new employment and consulting agreements with key executive officers and a medical officer, effective retroactively to January 1, 2011, or June 15, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms.
- CEO (Dr. Phillip P. Chan): Base compensation of $231,496 annually.
- CFO (David Lamadrid): Base compensation of $187,250 annually.
- COO (Vincent Capponi): Base compensation of $219,674 annually.
- CMO (Dr. Robert Bartlett): Consulting fee of $4,333.33 per month.
Material Changes
The primary material change is the formalization of executive compensation through new agreements:
- Renewed one-year employment agreements for the CEO, CFO, and COO, retroactive to January 1, 2011.
- Replacement of a prior April 2010 consulting agreement with Dr. Robert Bartlett with a new agreement effective June 15, 2011, extending through December 31, 2011.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. Key contractual terms and contingencies include:
- Termination: Employment may be terminated with 15 days' notice for "justifiable cause." The company may suspend employees without compensation pending legal adjudication of certain actions.
- Disability: Termination due to permanent disability triggers disability benefits after a 90-day waiting period.
- Non-Compete: Employees are prohibited from engaging in competing businesses in the U.S. and specified foreign areas for one year following separation.
- Confidentiality: Strict prohibitions on disclosing confidential information during and after employment.
Investor Verification Checklist
- Verify the total annual cash compensation obligation for the executive team ($638,420 for the three officers plus $52,000 for the CMO).
- Review the full text of Exhibits 10.1 through 10.4 for specific definitions of "justifiable cause" and non-compete geographic scope.
- Confirm the company's cash position to ensure it can meet these new fixed salary obligations.
- Check for any subsequent filings regarding the performance of clinical trials mentioned in the CMO's scope of work.